Clinical practice of renal cell carcinoma treatment with nivolumab

被引：0

作者：

Potocki, Pawel M. ^{[1
]}

Wysocki, Piotr J. ^{[1
]}

机构：

[1] Jagiellonian Univ, Coll Med, Dept Oncol, Krakow, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 05期

关键词：

kidney cancer; renal cell carcinoma; nivolumab; anti-PD-1; immunotherapy; checkpoint inhibitor; RANDOMIZED PHASE-3; CHECKMATE; 025; CANCER; EVEROLIMUS; IMMUNITY; SUNITINIB; BLOCKADE; EFFICACY; THERAPY; SAFETY;

D O I：

10.5603/OCP.2019.0002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nivolumab alike other immune checkpoint inhibitors has been intensively developed during the last decade. Kidney cancer is among the neoplasm in treatment of which we have accumulated the most experience regarding nivolumab. As improves our understanding of the mechanisms underlying specific cellular immune response, thus improves our understanding of the place the nivolumab holds among other therapeutic options. Recent years brought development of innovative immunotherapy combinations as a method for improving immunotherapy efficacy. This review aims at providing practicing oncologists with key aspects of renal cell carcinoma treatment with nivolumab.

引用

页码：237 / 245

页数：9

共 50 条

[21] Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Koshkin, Vadim S.
Barata, Pedro C.
Zhang, Tian
George, Daniel J.
Atkins, Michael B.
Kelly, William J.
Vogelzang, Nicholas J.
Pal, Sumanta K.
Hsu, JoAnn
Appleman, Leonard J.
Ornstein, Moshe C.
Gilligan, Timothy
Grivas, Petros
Garcia, Jorge A.
Rini, Brian I.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[22] Nivolumab Approved for Advanced Renal Cell Carcinoma
Schuyler, Devon
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (01) : 67 - 67
[23] Nivolumab in renal cell carcinoma patients in India
Rauthan, A.
Patil, P.
[J]. ANNALS OF ONCOLOGY, 2017, 28 : 85 - 85
[24] Treatment Algorithm for Metastatic Renal Cell Carcinoma - Recommendations Based on Evidence and Clinical Practice
Bergmann, Lothar
Beck, Jochaim
Bothe, Kathrin
Brinkmann, Olaf A.
Buse, Stephan
Goebell, Peter J.
Gruenwald, Viktor
Holzapfel, Konstantin
Kuebler, Hubert
Marschner, Norbert W.
Mickischk, Gerald
Schultze-Seemann, Wolfgang
Siebels, Michael
Siemer, Stephan
Stoerkel, Stephan
Gschwend, Juergen E.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (03) : 136 - 141
[25] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
Vitale, Maria Giuseppa
Nasso, Cecilia
Oltrecolli, Marco
Baldessari, Cinzia
Fanelli, Martina
Dominici, Massimo
Sabbatini, Roberto
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
[26] Renal Cell Carcinoma, Nivolumab Treatment, and 18F-FDGPET/CT
不详
[J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (06) : 26N - 26N
[27] PSOAS MUSCLE MASS PREDICTS THE OUTCOME OF NIVOLUMAB TREATMENT FOR RENAL CELL CARCINOMA
Ueki, Hideto
Okamura, Yasuyoshi
Bando, Yukari
Hara, Takuto
Terakawa, Tomoaki
Furukawa, Junya
Nakano, Yuzo
Fujisawa, Masato
[J]. JOURNAL OF UROLOGY, 2022, 207 (05): : E167 - E168
[28] Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma
Caner, Burcu
Ertas, Hulya
Ocak, Birol
Cubukcu, Erdem
[J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1645 - 1649
[29] Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma A Cost-Utility Analysis
Raphael, Jacques
Sun, Zhuolu
Bjarnason, Georg A.
Helou, Joelle
Sander, Beate
Naimark, David M.
[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (12): : 1235 - 1242
[30] Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
Venur, Vyshak Alva
Joshi, Monika
Nepple, Kenneth G.
Zakharia, Yousef
[J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1175 - 1182

← 1 2 3 4 5 →